{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:40:04Z","timestamp":1750534804367,"version":"3.41.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This case report explores the use of <jats:sup>177<\/jats:sup>Lu-DOTATATE in a hemodialysis patient. For the first time, this study assesses the average dose received by the bone marrow, the primary organ at risk, using an original double estimation method through independently acquired imaging and biological samples counting data. Despite elevated doses, the absorbed doses to the bone marrow (0.662\u20130.740 Gy) were within safe limits. Radiation protection measurements for staff were also compliant. This work supports that effective early dialysis and systematic personalized dosimetry are crucial for hemodialysis patients undergoing <jats:sup>177<\/jats:sup>Lu-PRRT due to their variability (residual excretion, treatment history, etc).<\/jats:p>","DOI":"10.1097\/rlu.0000000000005262","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T14:02:33Z","timestamp":1715263353000},"page":"648-649","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Dosimetric Considerations for 177Lu-DOTATATE Therapy in a Patient With Chronic Renal Failure Under Hemodialysis"],"prefix":"10.1097","volume":"49","author":[{"given":"Sarah","family":"Chaib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Tylski","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choaib","family":"Lachachi","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tassadit","family":"Keniza","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Levigoureux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"supplement 2","key":"bib1-20250621","first-page":"2251","article-title":"Clinical Lu-177-DOTATATE voxel-level Monte Carlo dosimetry for a patient with reduced kidney function undergoing hemodialysis","volume":"63","year":"2022","journal-title":"J Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2967\/jnumed.112.107524","article-title":"Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-Octreotate treatment","volume":"54","year":"2013","journal-title":"J Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40658-016-0157-0","article-title":"A novel planar image-based method for bone marrow dosimetry in 177Lu-DOTATATE treatment correlates with haematological toxicity","volume":"3","year":"2016","journal-title":"EJNMMI Phys"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","article-title":"Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate","volume":"36","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MNM.0000000000000232","article-title":"Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol","volume":"36","year":"2015","journal-title":"Nucl Med Commun"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40658-019-0243-1","article-title":"Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"6","year":"2019","journal-title":"EJNMMI Phys"},{"key":"bib8-20250621","first-page":"20150177","article-title":"177 Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis\u2014dosimetric considerations","volume":"1","year":"2015","journal-title":"BJRcase Rep"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7150\/thno.3645","article-title":"THERANOSTICS: from molecular imaging using Ga-68 labeled tracers and PET\/CT to personalized radionuclide therapy\u2014the Bad Berka experience","volume":"2","year":"2012","journal-title":"Theranostics"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:01:25Z","timestamp":1750532485000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005262","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}